Trial Profile
Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Nov 2022
Price :
$35
*
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Hypoplastic left heart syndrome
- Focus Adverse reactions
- Acronyms ELPIS
- 14 Nov 2022 According to Longeveron media release, the company has fully activated all 7 clinical sites and continues to enroll infants with HLHS.
- 21 Jun 2019 Status changed from recruiting to discontinued.
- 27 Feb 2018 According to Longeveron media release, trial has officially started with the first patient receiving the company's mesenchymal stem cell therapy in a procedure performed at the University of Maryland Medical Center in Baltimore.